Transthyretin Amyloid Cardiomyopathy Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Transthyretin Amyloid Cardiomyopathy remains an active clinical development field. Development is moving beyond single surrogate measures toward integrated cardiometabolic, renal and clinical-outcome evidence, with convenience and persistence becoming major differentiators. The PatSnap evidence set used here contains 102 matched trial records and 76 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| ChiCTR2600127950 | Intervention not normalized | Not Applicable; Not yet recruiting | Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences | China | Area under ROC curve of 99Tcm-PYP imaging for ATTR-CA diagnosis (After 99Tcm-PYP SPECT(/CT) scan, matched with pathological, genetic and…) | 2027-12-31 |
| NCT07695701 | Acoramidis | Phase 4; Not yet recruiting | Eidos Therapeutics, Inc. | Geography not listed | To assess the effect of acoramidis on cardiac function improvement by CMR in participants with ATTR-CM. (Month 36) | 2030-08-01 |
| NCT07690436 | Intervention not normalized | Not Applicable; Not yet recruiting | AstraZeneca PLC | United States, Portugal, Germany, Spain | Comparison of per-participant confidence scores distributions between ATTR-CM cases and HF controls without ATTR-CM (At a single assessment time point within 90 days following informed consent…); Qualitative assessment of features learned indicative of ATTR pathology (At a single assessment time point within 90 days following informed consent…) | 2027-06-03 |
| NCT07689331 | Intervention not normalized | Not Applicable; Recruiting | Semmelweis University | Hungary | Sex of Participants at Diagnosis (Baseline); Age at Diagnosis (Baseline) | 2028-05-01 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Vutrisiran in East Asian Patients With Transthyretin Amyloidosis With Cardiomyopathy (Phase 3): the indexed record reports Composite endpoint(all-cause mortality and recurrent cardiovascular events): HR = 0.2(95.0% CI, 0.04 - 0.93); Composite endpoint(all-cause mortality and recurrent cardiovascular events): HR = 0.2(95.0% CI, 0.04 - 0.93).
- Long-Term Efficacy of Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy by National Amyloidosis Centre stage (Phase 3): the indexed record reports CV-related mortality = 74 %; CV-related mortality = 55 %.
- HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) (Phase 3): the indexed record reports Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits) in the Overall Population = 125 Participants; Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits) in the Overall Population = 159 Participants; Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits) in the Overall Population: Hazard Ratio (HR) = 0.718(95% CI, 0.555 - 0.929), P-Value = 0.0118.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Acoramidis (Approved; TTR). Company & Deal Intelligence records identify sponsor context for Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences, Eidos Therapeutics, Inc. (EIDX), AstraZeneca PLC (AZN), Semmelweis University. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Active-comparator trials on top of contemporary standard of care.
- Hard cardiovascular, kidney or liver outcomes linked to earlier biomarker change.
- Evidence in underrepresented populations and patients with multiple comorbidities.
- Durability, adherence and post-discontinuation outcomes.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Transthyretin Amyloid Cardiomyopathy has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
